8-methoxy-3-methyl-1-propyl-imidazo[1,5-a]pyrido[3,2-e]pyrazine-4-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶吡嗪类
• 英文名称: 8-methoxy-3-methyl-1-propyl-imidazo[1,5-a]pyrido[3,2-e]pyrazine-4-one
• 英文别名: 2-methoxy-7-methyl-9-propylimidazo[1,5-a]pyrido[3,2-e]pyrazin-6(5H)-one；12-methoxy-5-methyl-3-propyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),3,5,10,12-pentaen-7-one
• 化学式: C₁₄H₁₆N₄O₂
• 分子量: 272.307
• InChiKey: AFXKDHNOPDSITL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  69
• 氢给体数：
  1
• 氢受体数：
  4

上下游信息

• 下游产品

  中文名称	英文名称	CAS号	化学式	分子量
  ——	4-ethyl-8-methoxy-3-methyl-1-propyl-imidazo[1,5-a]pyrido[3,2-e]pyrazine	——	C16H20N4O	284.361
  ——	4-amino-8-methoxy-3-methyl-1-propyl-imidazo[1,5-a]pyrido[3,2-e]pyrazine	959706-53-7	C14H17N5O	271.322
  ——	4-chloro-8-methoxy-3-methyl-1-propyl-imidazo[1,5-a]pyrido[3,2-e]pyrazines	959706-26-4	C14H15ClN4O	290.752
  ——	4-chloro-3-methyl-1-propyl-imidazo[1,5-a]pyrido[3,2-e]pyrazin-8-ol	959706-49-1	C13H13ClN4O	276.725

反应信息

• 作为反应物：
  描述：

  8-methoxy-3-methyl-1-propyl-imidazo[1,5-a]pyrido[3,2-e]pyrazine-4-one 在 氨 、 三氯氧磷 作用下， 以 水 为溶剂， 反应 16.0h， 生成 4-amino-8-methoxy-3-methyl-1-propyl-imidazo[1,5-a]pyrido[3,2-e]pyrazine
  参考文献：
  名称：

  WO2007/137820

  摘要：

  公开号：
• 作为产物：
  描述：

  4-甲基-2-丙基-1H-咪唑 在 palladium on activated charcoal 氢氧化钾 、 氢气 作用下， 以 乙醇 、 溶剂黄146 、 N,N-二甲基甲酰胺 为溶剂， 5.0~160.0 ℃ 、1.5 MPa 条件下， 反应 9.25h， 生成 8-methoxy-3-methyl-1-propyl-imidazo[1,5-a]pyrido[3,2-e]pyrazine-4-one
  参考文献：
  名称：

  WO2007/137820

  摘要：

  公开号：

文献信息

• Methods of Treating Obesity and Metabolic Disorders
  申请人：Hofgen Norbert

  公开号：US20090143392A1

  公开（公告）日：2009-06-04

  The invention relates to methods of treating or preventing obesity, type 2 diabetes, metabolic syndrome, or glucose intolerance using pyrido[3,2-e]pyrazines which are inhibitors of PDE10. The invention further relates to methods of reducing body fat or body weight.

  本发明涉及使用PDE10抑制剂pyrido [3,2-e] pyrazines治疗或预防肥胖症、2型糖尿病、代谢综合征或葡萄糖不耐症的方法。本发明还涉及减少体脂肪或体重的方法。
• Discovery of Imidazo[1,5-<i>a</i>]pyrido[3,2-<i>e</i>]pyrazines as a New Class of Phosphodiesterase 10A Inhibitiors
  作者：Norbert Höfgen、Hans Stange、Rudolf Schindler、Hans-Joachim Lankau、Christian Grunwald、Barbara Langen、Ute Egerland、Peter Tremmel、Menelas N. Pangalos、Karen L. Marquis、Thorsten Hage、Boyd L. Harrison、Michael S. Malamas、Nicholas J. Brandon、Thomas Kronbach

  DOI：10.1021/jm1002793

  日期：2010.6.10

  Novel imidazo[1,5-a]pyrido[3,2-e]pyrazines have been synthesized and characterized as both potent and selective phosphodiesterase 10A (PDE10A) inhibitors. For in vitro characterization, inhibition of PDE10A mediated cAMP hydrolysis was used and a QSAR model was established to analyze substitution effects. The outcome of this analysis was complemented by the crystal structure of PDE10A in complex with compound 49. Qualitatively new interactions between inhibitor and binding site were found, contrasting with previously published crystal structures of papaverine-like inhibitors. In accordance with the known antipsychotic potential of PDE10A inhibitors, MK-801 induced stereotypy and hyperactivity in rats were reversed by selected compounds. Thus, a promising compound class has been identified for the treatment of schizophrenia that could circumvent side effects connected with current therapies.
• WO2007/137819
  申请人：——

  公开号：——

  公开（公告）日：——
• [EN] METHODS OF TREATING OBESITY AND METABOLIC DISORDERS<br/>[FR] PROCÉDÉS DE TRAITEMENT DE L'OBÉSITÉ ET DE TROUBLES MÉTABOLIQUES
  申请人：ELBION GMBH

  公开号：WO2009068246A2

  公开（公告）日：2009-06-04

  The invention relates to methods of treating or preventing obesity, type 2 diabetes, metabolic syndrome, or glucose intolerance using pyrido[3,2-e]pyrazines which are inhibitors of PDE 10. The invention further relates to methods of reducing body fat or body weight.
• WO2007/137820
  申请人：——

  公开号：——

  公开（公告）日：——